Drug intelligence / Profile preview

ODA-579

Development stage: Preclinical
Lead developer: Ocean Biomedical
Modality: Small Molecules
Administration: Oral

Overview

ODA-579 is an investigational **small molecule drug** being developed as an anti-malarial agent. It acts against *Plasmodium falciparum* by targeting the parasite antigen **PfGARP** (Plasmodium falciparum Glutamic Acid–Rich Protein), which is implicated in parasite growth arrest and survival. ODA-579 is designed to treat symptomatic P. falciparum infection by interfering with this malaria protein, potentially representing a new class of anti-malarial therapies[7].

Targets

GLURP (Plasmodium falciparum glutamate-rich protein)

Beyond the preview

Go deeper on ODA-579.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODA-579.

Explore the full profile